Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can't kick that oncogene habit.

Gerard I Evan1

  • 1Cancer Research Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco Comprehensive Cancer Center, 2340 Sutter Street, San Francisco, California 94143, USA. gevan@cc.ucsf.edu

Cancer Cell
|November 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum: Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Genes & development·2026
Same author

Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolution.

Nature cell biology·2026
Same author

Corrigendum to Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.

The Journal of clinical investigation·2025
Same author

A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis.

Nature immunology·2025
Same author

A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.

Nature communications·2023
Same author

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.

Nature·2023
Same journal

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
See all related articles

Targeted cancer therapies are enhanced by intracellular signaling dynamics. This innate asymmetry favors cell death, improving treatment efficacy against specific oncogenic pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Modern cancer treatment shifts from cytotoxic agents to targeted therapies inhibiting specific oncogenic pathways.
  • This strategy assumes cancer maintenance relies on a limited set of targetable genetic alterations.
  • Sharma et al. investigate the role of intracellular signaling in cancer treatment efficacy.

Discussion:

  • The study reveals an inherent asymmetry in intracellular signaling dynamics.
  • This asymmetry naturally biases pathway inhibition towards inducing cancer cell death.
  • This finding supports the efficacy of targeted cancer therapies.

Key Insights:

  • Evolutionary dynamics favor targeted cancer therapies by creating signaling asymmetries.
  • Intracellular signaling bias potentiates the effectiveness of drugs targeting specific oncogenic pathways.

Related Experiment Videos

  • This mechanism offers a new perspective on overcoming cancer resistance.

    • Outlook:

    • Further research can explore exploiting this signaling bias for novel therapeutic strategies.
    • Understanding these dynamics may lead to more personalized and effective cancer treatments.
    • This work highlights the potential of integrating evolutionary principles into cancer drug development.